C
Chi Young Ok
Researcher at University of Texas MD Anderson Cancer Center
Publications - 110
Citations - 2403
Chi Young Ok is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Mantle cell lymphoma & Medicine. The author has an hindex of 22, co-authored 94 publications receiving 1783 citations. Previous affiliations of Chi Young Ok include University of Massachusetts Medical School & University of Massachusetts Boston.
Papers
More filters
Journal ArticleDOI
EBV-positive diffuse large B-cell lymphoma of the elderly
TL;DR: This review comprehensively delineates the data emerging from analyses of EBV latency program, microRNA-mediated EBV viral oncogenesis, functional genomics ofEBV and its biology, and differential diagnosis challenge for EBV-positive DLBCL of the elderly.
Journal ArticleDOI
Prevalence and clinical implications of epstein-barr virus infection in de novo diffuse large B-cell lymphoma in Western countries.
Chi Young Ok,Ling Li,Zijun Y. Xu-Monette,Carlo Visco,Alexander Tzankov,Ganiraju C. Manyam,Santiago Montes-Moreno,Karen Dybaer,April Chiu,Attilio Orazi,Youli Zu,Govind Bhagat,Jiayu Chen,Kristy L. Richards,Eric D. Hsi,William W.L. Choi,J. Han van Krieken,Jooryung Huh,Weiyun Z. Ai,Maurilio Ponzoni,Andrés J.M. Ferreri,John P. Farnen,Michael Boe Møller,C. E. Bueso-Ramos,Roberto N. Miranda,Jane N. Winter,Miguel A. Piris,L. Jeffrey Medeiros,Ken H. Young +28 more
TL;DR: The clinical characteristics of patients with EBV+ versus EBV− DLBCL are similar and EBV infection does not predict a worse outcome and CD30 expression combined withEBV conferred an inferior outcome, but GEP showed a unique expression signature in EBV+.
Journal ArticleDOI
Checkpoint inhibitors in hematological malignancies
Chi Young Ok,Ken H. Young +1 more
TL;DR: Clinical trials demonstrated that PD-1 blockade is an attractive way to restore host’s immune function in hematological malignancies, particularly classical Hodgkin lymphoma, and pursuit to discover the best biomarker is ongoing.
Journal ArticleDOI
Mutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseases
Chi Young Ok,Keyur P. Patel,Guillermo Garcia-Manero,Mark J. Routbort,Bin Fu,Bin Fu,Guilin Tang,Maitrayee Goswami,Rajesh R. Singh,Rashmi Kanagal-Shamanna,Sherry Pierce,Ken H. Young,Hagop M. Kantarjian,L. Jeffrey Medeiros,Rajyalakshmi Luthra,Sa A. Wang +15 more
TL;DR: Next generation sequencing-based approach to profile gene mutations in therapy-related myelodysplastic syndromes (t-MDS) and acute myeloid leukemia ( t-AML) and compared these findings with de novo MDS/AML shows a mutation profile different from their de noovo counterparts.
Journal ArticleDOI
TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases
Chi Young Ok,Keyur P. Patel,Guillermo Garcia-Manero,Mark J. Routbort,Jie Peng,Jie Peng,Guilin Tang,Maitrayee Goswami,Ken H. Young,Rajesh R. Singh,L. Jeffrey Medeiros,Hagop M. Kantarjian,Rajyalakshmi Luthra,Sa Wang +13 more
TL;DR: The findings support the recent notion that heterozygous TP53 mutation may be a function of normal aging and that mutated cells are subject to selection upon exposure to cytotoxic therapy.